Associate Professor of Medicine, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Member of the Healthcare Council
Charles Ryan, MD, is Associate Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco. His focus is on clinical research for prostate cancer include hormonal therapies, drug development strategies utilizing targeted therapies as well as angiogenesis inhibitors, chemotherapy, and tumor vaccines. Dr. Ryan has experience in the study of genomic profiles of prostate tumors following androgen deprivation therapy. He has authored numerous publications in the area of prostate cancer and is an investigator on a number of active clinical trials both within the University of California San Francisco and through national cooperative groups. (This is me - Update Profile)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Phase III Ascentar (NOVC) Study Halted - Ineffective Drug or Faulty Trial Design?
November 8, 2007
Novacea Halts ASCENT-2 Trial in Advanced Prostate Cancer | www.therapeuticsdaily.com
Prior studies had suggested an improvement in survival when calcitriol was added to weekly docetaxel. The premature closure of this study ocurred due to an increased death rate in patients receiving the combination of weekly docetaxel compared to q 21 day docetaxel. Faulty trial design, and not necessarily inactivity of the drug, may be to blame for this. Competing trials in this space include the Docetaxel Plus GVAX phase III (Cell Genesys) and the Docetaxel plus Bevacizumab phase III study (US Cooperative Group/Genentech)
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Oncologists (US) | 2241 |
| Urologic Oncologists (US) | 146 |
| Medical Geneticists (US) | 85 |
Charles Ryan has not participated in any GLG Live Meetings.